In this issue:
Ipilimumab +/- nivolumab in PD-1 or PD-L1 MM
Trends and patterns of care of sentinel node biopsy in cutaneous melanoma
Deep learning-based scoring of tumour-infiltrating lymphocytes
Treatment management for BRAFmutant melanoma patients with tumour recurrence
Outcomes of invasive melanoma of the head and neck treated with MMS
Seven-year follow-up of the phase III KEYNOTE-006 study
Efficacy of immune checkpoint inhibitors for the treatment of CLL
Long-term outcomes of neoadjuvant pembrolizumab
Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma
Please login below to download this issue (PDF)